List of Excipients in Branded Drug CAPECITABINE 150MG

Generic Drugs Containing CAPECITABINE 150MG

Company	Ingredient	NDC	Excipient
Armas Pharmaceuticals Inc	capecitabine	72485-204	ANHYDROUS LACTOSE
Armas Pharmaceuticals Inc	capecitabine	72485-204	CELLULOSE, MICROCRYSTALLINE
Armas Pharmaceuticals Inc	capecitabine	72485-204	CROSCARMELLOSE SODIUM
Armas Pharmaceuticals Inc	capecitabine	72485-204	FERRIC OXIDE RED
Armas Pharmaceuticals Inc	capecitabine	72485-204	FERRIC OXIDE YELLOW
Armas Pharmaceuticals Inc	capecitabine	72485-204	HYPROMELLOSE
Armas Pharmaceuticals Inc	capecitabine	72485-204	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in CAPECITABINE 150MG?

# Of NDCs	Excipient
2	ANHYDROUS LACTOSE
2	CELLULOSE, MICROCRYSTALLINE
2	CROSCARMELLOSE SODIUM
2	FERRIC OXIDE RED
2	FERRIC OXIDE YELLOW
2	HYPROMELLOSE
2	MAGNESIUM STEARATE

Capecitabine 150 mg Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Capecitabine 150 mg is a mature immediate-release oral chemotherapy strength with limited opportunity for molecule-level differentiation. Commercial value is concentrated in reliable generic supply, low-cost tablet manufacturing, dose flexibility, packaging quality, and excipient control. The strongest strategy is a robust, bioequivalent film-coated tablet using conventional compendial excipients, supported by a validated impurity-control program and differentiated supply arrangements for oncology distributors and institutional buyers.

What is capecitabine 150 mg used for?

Capecitabine is an oral prodrug converted to 5-fluorouracil through enzymatic activation. FDA-approved uses include metastatic colorectal or breast cancer, adjuvant treatment of colon cancer, and certain breast cancer indications after prior chemotherapy. The 150 mg tablet is generally used with higher-strength tablets to construct patient-specific doses rather than as the sole commercial dose strength [1].

Attribute	Capecitabine 150 mg
Active ingredient	Capecitabine
Dosage form	Immediate-release film-coated tablet
Route	Oral
Typical higher adult dose	1,250 mg/m² twice daily in several labeled settings
Role of 150 mg strength	Dose assembly, titration, dose reduction, and regimen flexibility
Reference product	Xeloda
Regulatory pathway for generics	ANDA with comparative bioequivalence
Biologic status	Small-molecule drug; biosimilar pathway does not apply
Primary commercial market	Generic oncology and hospital supply

The 150 mg strength has commercial relevance because capecitabine dosing is based on body-surface area and is frequently modified for renal impairment, toxicity, age, drug interactions, and treatment tolerance. A manufacturer that supplies only 500 mg tablets may leave pharmacies and hospitals dependent on tablet splitting or mixed-strength sourcing. A complete portfolio normally includes 150 mg and 500 mg tablets.

What excipients are used in capecitabine 150 mg tablets?

The reference-product formulation uses conventional tablet excipients. Public labeling identifies excipient classes that include anhydrous lactose, croscarmellose sodium, hypromellose, microcrystalline cellulose, magnesium stearate, and film-coating components such as titanium dioxide, talc, and iron oxides [1,2].

A practical generic formulation can use the following functional architecture:

Formulation function	Candidate excipient	Commercial purpose
Diluent and compressibility aid	Microcrystalline cellulose	Supports tablet hardness and content uniformity
Diluent	Anhydrous lactose or alternative filler	Controls bulk density and tablet weight
Superdisintegrant	Croscarmellose sodium	Promotes rapid tablet breakup
Binder or coating polymer	Hypromellose	Supports granulation and film coating
Lubricant	Magnesium stearate	Reduces ejection force and tooling adhesion
Opacifier and colorant	Titanium dioxide, iron oxides	Provides product identification and light protection
Coating aid	Talc	Improves coating processability

The formulation target is not maximum excipient novelty. It is rapid and reproducible disintegration, acceptable dissolution across the approved pH range, low tablet friability, stable appearance, and minimal batch-to-batch variability.

How should the excipient strategy be designed?

The preferred development path is a conventional immediate-release formulation with a narrow critical-quality-attribute profile.

Core formulation objectives

The 150 mg tablet should be designed to achieve:

• Uniform capecitabine content across the batch
• Rapid disintegration without excessive friability
• Dissolution comparable to the reference product
• Low sensitivity to lubricant overmixing
• Stable moisture and impurity performance
• Reliable film-coating adhesion
• Efficient compression at commercial scale
• Acceptable tablet size for oncology patients taking multiple tablets

Capecitabine has limited formulation value from extended-release technology because the approved product is immediate release and the clinical dosing regimen depends on prompt systemic exposure. A modified-release product would require a separate clinical and regulatory strategy and would compete in a market dominated by low-cost immediate-release generics.

Direct compression versus wet granulation

Direct compression can reduce manufacturing steps and cost, but it requires excipients with consistent flow, compressibility, and particle-size distribution. Wet granulation may provide better content uniformity and tablet robustness when the active pharmaceutical ingredient has poor flow or segregation risk.

Development option	Advantages	Main risks
Direct compression	Lower process complexity, lower solvent use, shorter cycle time	Segregation, capping, poor flow, sensitivity to raw-material variability
Wet granulation	Improved flow, content uniformity, stronger tablets	Higher process cost, residual moisture, degradation risk
Dry granulation	No aqueous exposure, scalable compaction	Ribbon-density variability, granule fracture, dissolution changes

A risk-based development program should compare at least two manufacturing routes at laboratory and pilot scale. The selected route should be determined by blend uniformity, dissolution, impurity formation, and scale-up reproducibility rather than by nominal process cost alone.

What formulation patents protect capecitabine 150 mg?

Capecitabine 150 mg has limited opportunity for new formulation-patent value because the active ingredient and reference immediate-release product are mature. Commercial protection is more likely to arise from manufacturing controls, crystalline or particle-engineering work, packaging, or a differentiated formulation with clinical support.

Potential patentable areas include:

• Narrow particle-size distributions that improve blend uniformity
• Specific granulation processes
• Low-impurity manufacturing methods
• Stabilized compositions with defined moisture limits
• Taste-masked or dispersible dosage forms
• Combination packs or dose-assembly systems
• Alternate dosage forms for patients unable to swallow tablets
• Use of specific excipient ratios that produce a defined dissolution profile

A routine substitution of one standard filler for another is unlikely to create durable patent value by itself. The formulation must show a measurable technical effect, such as improved stability, reduced degradation, improved dissolution after storage, or better dose uniformity.

What is the Orange Book status of capecitabine?

Capecitabine is a small-molecule prescription drug listed in the FDA Orange Book. The reference product is Xeloda, originally associated with Roche and Genentech. The product has long been exposed to generic competition, and capecitabine tablets are available through multiple generic manufacturers in the United States.

The main regulatory pathway is an abbreviated new drug application. Generic applicants generally must demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug. For a conventional immediate-release tablet, the commercial barrier is therefore formulation execution, manufacturing compliance, analytical capability, and supply reliability rather than the need to repeat the originator’s efficacy trials [3].

Does capecitabine have biosimilar risk?

No. Capecitabine is not a biologic. Biosimilar rules under the Public Health Service Act do not apply. Competitive pressure comes from ANDA-approved generic tablets, authorized-generic strategies, institutional contracting, and potential international manufacturers.

When does capecitabine lose exclusivity?

The principal capecitabine exclusivity period has already ended in the United States. Originator patent and regulatory protections are no longer the central market constraint for the 150 mg tablet. Current commercial access depends on FDA approval, manufacturing capacity, product quality, and payer or distributor contracting.

A generic applicant should still review the current Orange Book for listed patents, pediatric exclusivity, or other entry-relevant information before filing. Historical patent expiration does not eliminate the need to assess any current listed claims associated with a particular reference-product presentation [3].

What paragraph IV challenges affect capecitabine?

Paragraph IV litigation was relevant during the historical transition from Xeloda exclusivity to generic entry. A paragraph IV certification asserts that a listed patent is invalid, unenforceable, or not infringed. For a mature product with multiple approved generics, the commercial importance of a new paragraph IV strategy is generally lower than it was during the initial generic-entry window.

The practical legal review should focus on:

1. Current Orange Book listings.
2. Any unexpired formulation or method-of-use claims.
3. Pending Hatch-Waxman litigation.
4. Thirty-month-stay exposure.
5. Settlement terms affecting launch timing.
6. Whether the applicant seeks a section viii statement for a protected indication.

Capecitabine’s mature generic market reduces the expected value of litigation-driven exclusivity unless a new formulation or use creates a commercially meaningful niche.

What method-of-use patents protect capecitabine?

Method-of-use claims may cover specific cancer indications, dosing schedules, combination regimens, or patient populations. A generic applicant can seek approval for non-protected indications through a section viii statement where permitted, while omitting patented uses from labeling.

The 150 mg tablet itself is usually commercialized for broad dose flexibility across labeled oncology regimens. This creates a labeling and risk-management issue: the applicant must align its proposed labeling with the reference product and any applicable patent carve-outs. Method-of-use risk is therefore more relevant to label design and launch timing than to the basic excipient composition.

How strong is the patent estate for capecitabine 150 mg?

The patent estate is commercially weak as a barrier to conventional generic tablets because the product is mature and widely genericized. A new entrant’s defensibility is more likely to come from execution than from composition-of-matter protection.

Protection category	Expected relevance for a conventional 150 mg generic
Active-ingredient patent	Low
Standard immediate-release composition	Low
Method-of-use claims	Moderate, depending on label
Manufacturing-process claims	Moderate
Specialty dosage-form claims	Potentially high, if clinically differentiated
Trade secrets and process know-how	High for quality and yield
Supply-chain qualification	High for institutional contracts

Process know-how may include granulation endpoint control, coating uniformity, impurity suppression, cleaning validation, and packaging moisture control. These assets are difficult to enforce as patents but can protect cost and quality performance.

What manufacturing and IP barriers exist?

Manufacturing barriers are moderate rather than technologically extreme. Capecitabine is not a biologic, sterile injectable, or highly complex delivery system. The most important risks are chemical and operational.

Key technical risks

• Active-ingredient segregation during blending
• Inadequate content uniformity at the 150 mg dose
• Lubrication-induced dissolution slowdown
• Moisture-related degradation
• Coating color variability
• Tablet chipping and friability
• Impurity growth during accelerated stability
• Cross-contamination controls in oncology manufacturing
• API supply concentration
• Serialization and packaging compliance

The 150 mg tablet can be disproportionately sensitive to blend uniformity because it contains less active ingredient than the 500 mg strength. Process capability should be established around assay, content uniformity, dissolution, friability, hardness, disintegration, impurities, and coating weight gain.

What commercial opportunities exist for capecitabine 150 mg?

The opportunity is primarily a volume-and-service business. Potential segments include:

Institutional generic supply

Hospitals, oncology centers, group purchasing organizations, and specialty distributors value dependable supply across both 150 mg and 500 mg strengths. A supplier with dual-strength availability can reduce pharmacy substitutions and treatment delays.

Dose-flexibility portfolio

A full strength portfolio supports dose reductions and patient-specific regimens. Packaging 150 mg and 500 mg tablets under the same manufacturer identity can increase formulary utility.

Contract manufacturing

Capecitabine can fit a contract-development-and-manufacturing portfolio for oral oncology products. The strongest offering combines API sourcing, formulation, analytical method transfer, stability data, serialization, and finished-dose packaging.

Regional registration

Markets outside the United States may offer opportunities where generic penetration is lower or where local manufacturing is favored. The product is suitable for decentralized packaging and multiple market-specific presentations, subject to local pharmaceutical regulations.

Patient-support packaging

Calendar packs, clear strength differentiation, and warning-oriented labeling can reduce dispensing errors. Packaging is not a substitute for clinical differentiation, but it can support hospital procurement and pharmacy preference.

Supply resilience

A new manufacturer can compete through dual API sources, safety stock, validated alternate packaging, and shorter lead times. In a mature generic market, these factors often matter more than a marginal reduction in tablet cost.

How does capecitabine compare with competing oral fluoropyrimidines?

Product	Active ingredient	Dosage-form complexity	Generic competition	Excipient opportunity
Capecitabine	Capecitabine	Low to moderate	High	Manufacturing and packaging
5-fluorouracil injection	Fluorouracil	Sterile injectable	High	Sterility, container closure, stability
Tegafur-based products	Tegafur, often in combinations	Moderate	Region-dependent	Combination formulation and regional access
S-1	Tegafur/gimeracil/oteracil	Combination oral capsule	Region-dependent	Multi-active compatibility and dose ratios

Capecitabine has a lower technical barrier than sterile fluorouracil but a more crowded generic market. Its commercial advantage is oral administration and established oncology use. Its weakness is limited ability to command premium pricing without a differentiated service, dosage form, or market-access position.

What revenue exposure exists for a capecitabine 150 mg launch?

Revenue exposure depends on tablet volume, payer discounts, wholesaler concentration, and whether the company sells both strengths. The 150 mg strength should not be evaluated as an isolated product because many regimens require mixed-strength dosing.

A simple commercial model is:

Driver	Effect on opportunity
150 mg and 500 mg portfolio	Increases account retention and regimen coverage
Reliable fill rate	Supports hospital and distributor contracts
Low-cost API	Improves gross margin
Multiple qualified API suppliers	Reduces supply interruption risk
Specialty packaging	May improve procurement preference
Price-only strategy	Risks rapid margin compression
Single-strength launch	Limits formulary utility

The most defensible strategy is to position 150 mg as part of a complete capecitabine platform rather than as a standalone SKU.

What generic launch scenarios exist?

Base-case launch

A conventional immediate-release 150 mg tablet enters a competitive market with limited pricing power. Success depends on approval timing, launch inventory, API cost, and distributor access.

Premium-reliability launch

The product is priced near the generic market but differentiated through dual sourcing, high fill rates, and integrated 150 mg/500 mg supply. This model is more suitable for hospitals and specialty distributors.

Specialty-formulation launch

A dispersible, easier-to-swallow, or modified presentation targets a defined patient segment. This path requires stronger clinical, regulatory, and intellectual-property support and carries materially higher development risk.

Regional partnership launch

A manufacturer licenses or co-develops the product with a local marketing authorization holder. This can reduce market-entry cost but transfers margin and control to the partner.

Key Takeaways

• Capecitabine 150 mg is a mature generic oncology opportunity, not a conventional new-molecule patent opportunity.
• The preferred formulation is an immediate-release film-coated tablet using established excipients such as lactose, microcrystalline cellulose, croscarmellose sodium, hypromellose, and magnesium stearate.
• Content uniformity, dissolution, moisture control, and impurity management are the main technical priorities.
• The 150 mg tablet has higher strategic value when launched with the 500 mg strength.
• Biosimilar risk does not apply because capecitabine is a small molecule.
• Current commercial barriers are manufacturing quality, supply continuity, procurement access, and regulatory execution.
• New patent value is more plausible for specialized dosage forms, process controls, or technically demonstrated stability improvements than for routine excipient substitutions.
• The strongest commercial positioning is a reliable dual-strength oncology supply platform.

FAQs

Can capecitabine 150 mg tablets use lactose-free excipients?

Yes. A lactose-free formulation is technically feasible, but it requires comparative dissolution, stability, manufacturability, and bioequivalence support. The substitution must not compromise tablet hardness, disintegration, or content uniformity.

Is capecitabine 150 mg suitable for direct compression?

It may be suitable if the API and excipient blend provide adequate flow, compressibility, and segregation control. Wet or dry granulation may be preferable when direct compression produces unacceptable uniformity or mechanical performance.

Can a manufacturer patent a new capecitabine 150 mg excipient combination?

Potentially, but routine substitution is unlikely to provide strong protection. A defensible claim generally requires a demonstrated technical effect, such as improved stability, dissolution, impurity control, or dose uniformity.

Does capecitabine require a bioequivalence study for an ANDA?

An ANDA generally requires evidence that the proposed product is pharmaceutically equivalent and bioequivalent to the reference listed drug. FDA may also require comparative dissolution and other product-quality information based on the product and regulatory pathway [3].

Is the 150 mg strength commercially viable without the 500 mg strength?

It can be approved and sold independently, but its commercial value is usually lower. Pharmacies and oncology institutions commonly prefer suppliers that can provide the full strength combination needed for standard dosing and dose modification.

References

1. U.S. Food and Drug Administration. (2022). Xeloda (capecitabine) tablets prescribing information. Genentech, Inc.

2. National Library of Medicine. (2024). Capecitabine tablet, film coated: DailyMed drug label. U.S. National Library of Medicine.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (2015). Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. Guidance for Industry.